Ua holomua ka papa I ka lāʻau hou o JYMed, ua manaʻo ʻia ʻo Laipushutai e lilo i laina mua o nā lāʻau lapaʻau UC.

Ma Iune 29, 2017, ka hoʻomohala ʻana o Laipushutai, ka papa I ka lāʻau lapaʻau hou me ka hoʻomohala ʻana o JYMed a me Guangzhou Linkhealth Medical Technology Co., Ltd., ua holomua nui.Ua ʻae ʻia ka ʻōlelo IND o ka lāʻau lapaʻau e ka CFDA.

Ua hōʻea ʻo JYMed a me Guangzhou Linkhealth Medical Technology Co., Ltd. i kahi ʻaelike hui ma 2016 e hoʻomohala pū i kēia huahana ma Kina.Ua hoʻopau ka ʻano i nā haʻawina hoʻokolohua POC ma EU a loaʻa i ka palekana palekana a me nā kala kala.Hoʻomaopopo ka FDA a me ka EMA e hiki ke hoʻohana ʻia kēia ʻano no ka mālama ʻana ma ka laina I/II, a e hāʻawi ʻia ka mea nui i ka hoʻomaha a me ka mālama ʻana i nā maʻi me ka ulcerative colitis haʻahaʻa ma hope o nā hoʻokolohua lapaʻau o CFDA.

ʻO ka Ulcerative colitis (UC) kahi maʻi ʻehaʻeha a ʻaʻole kikoʻī e kū mai ana i loko o ka rectum a me ke kolonā.Wahi a nā helu helu, ʻo ka helu helu o UC he 1.2 a 20.3 mau hihia / 100,000 kanaka i kēlā me kēia makahiki a ʻo ka prevalence o UC he 7.6 a 246.0 mau hihia/10,000 poʻe i kēlā me kēia makahiki.ʻOi aku ka maʻamau o ka UC i nā ʻōpio makua.Loaʻa i ka mākeke UC ka nui a me ke koi ʻana i nā lāʻau lapaʻau, a e hoʻomau i ka ulu ulu kiʻekiʻe i ka wā e hiki mai ana.I kēia manawa, hoʻokumu nui ʻia ka lāʻau lapaʻau mua o ka UC ma ka mesalazine a me nā hormones, a ʻo nā lāʻau lapaʻau ʻelua me nā immunosuppressants a me nā antibodies monoclonal biological.Loaʻa iā Mesalazine kahi kūʻai kūʻai o 1 biliona ma Kina a me US $ 2 biliona ma ʻAmelika Hui Pū ʻIa i 2015. ʻOi aku ka maikaʻi o ka pane ʻana o Laipushutai i nā hōʻailona UC, a ʻoi aku ka palekana ma mua o nā lāʻau lapaʻau mua.Loaʻa iā ia kahi pōmaikaʻi mākeke maikaʻi a manaʻo ʻia e lilo i lāʻau lapaʻau UC laina mua.